NEW HOPE, Pa. — February 19, 2026 — Leads & Copy — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will participate in upcoming institutional investor conferences, the company announced today.
Management from the biomedical company will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, from March 2-4, 2026. A live fireside chat is scheduled for Tuesday, March 3rd, at 9:50 a.m. ET. The company will also host one-on-one meetings with investors. The event will be accessible via a live webcast, available on Orchestra BioMed’s Investor Relations website.
Orchestra BioMed will also participate in the Barclays 28th Annual Global Healthcare Conference in Miami, FL, from March 10-12, 2026. Management will participate in a live fireside chat on Wednesday, March 11th, at 8:00 a.m. ET, and will host one-on-one meetings with investors. This event will also be accessible via a live webcast on the company’s Investor Relations website.
Orchestra BioMed is focused on accelerating high-impact technologies to patients through collaborations with medical device companies. The company’s product candidates include Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB).
AVIM Therapy, a bioelectronic treatment for hypertension, is designed as a firmware upgrade to a pacemaker, to reduce blood pressure in hypertensive heart disease patients. The company has a collaboration with Medtronic for the development and commercialization of AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients. The FDA has granted AVIM Therapy Breakthrough Device Designation for these patients, estimating 7.7 million total patients in the U.S. with uncontrolled hypertension.
Virtue SAB is a non-coated drug delivery angioplasty balloon system designed to deliver a liquid dose of SirolimusEFR™ for the treatment of atherosclerotic artery disease. The FDA has granted Virtue SAB Breakthrough Device Designation for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.
Source: Orchestra BioMed
